Table 4.

Adjusted change in anemia measurements for black and nonblack patients across three time periods

OutcomeMonthly Δ (95% CI): August 2010–December 2010 Pre-PPSMonthly Δ (95% CI): January 2011–June 2011 Post-PPS/Pre-ESA Label ChangeMonthly Δ (95% CI): July 2011–December 2011 Post-ESA Label ChangeP Value for Difference in Trends by Race
NonblackBlackNonblackBlackNonblackBlack
Hgb (g/dl)0.02 (−0.04 to 0.01)−0.04 (−0.08 to 0.00)−0.01 (−0.02 to 0.01)−0.00 (−0.02 to 0.02)−0.07 (−0.09 to −0.05)−0.06 (−0.11 to −0.02)0.63
Patients with Hgb<9 g/dl (%)−0.04 (−0.27 to 0.19)0.04 (−0.35 to 0.42)0.04 (−0.11 to 0.18)−0.07 (−0.32 to 0.19)0.19 (0.02 to 0.36)0.62 (0.15 to 1.10)0.37
Patients with Hgb<10 g/dl (%)0.03 (−0.36 to 0.43)0.45 (−0.34 to 1.23)−0.01 (−0.32 to 0.30)−0.23 (−0.81 to 0.34)1.24 (0.83 to 1.66)1.64 (0.68 to 2.59)0.64
Patients with Hgb>12 g/dl (%)−0.63 (−1.44 to 0.18)−1.57 (−2.84 to −0.30)−0.47 (−0.95 to 0.02)−0.26 (−0.90 to 0.38)−1.35 (−1.92 to −0.79)−0.70 (−2.01 to 0.61)0.39
Patients with ESA use (%)−1.40 (−1.98 to −0.81)−1.57 (−2.53 to −0.61)−0.41 (−0.95 to 0.13)0.15 (−0.34 to 0.65)−0.78 (−1.41 to −0.14)−0.98 (−1.71 to −0.24)0.40
Prescribed IV EPO dose (U/wk)−160 (−566 to 246)−353 (−831 to 124)−224 (−448 to 0)−278 (−541 to −15)−647 (−838 to −457)−648 (−930 to −366)0.74
Patients with prescribed IV EPO dose≥30,000 U/wk (%)−0.29 (−1.31 to 0.73)−0.56 (−1.69 to 0.56)−0.66 (−1.10 to −0.21)−0.46 (−0.97 to 0.06)−0.66 (−1.03 to −0.28)−1.34 (−2.12 to −0.57)0.30
Delivered IV EPO dose (U/wk)a−554 (−879 to −229)−500 (−858 to −142)−108 (−310 to 95)−91 (−306 to 125)−639 (−842 to −436)−705 (−1021 to −390)0.98
Patients with IV iron use (%)1.69 (0.26 to 3.11)1.52 (−0.26 to 3.31)1.14 (0.08 to 2.19)1.40 (−0.33 to 3.14)−1.79 (−2.63 to −0.94)−0.84 (−1.84 to 0.15)0.23
Prescribed IV Iron dose (mg/mo)10.20 (1.94 to 18.47)6.81 (−4.90 to 18.53)−7.98 (−17.75 to 1.79)−3.23 (−14.21 to 7.74)−1.76 (−5.32 to 1.80)−2.35 (−7.88 to 3.18)0.84
Delivered IV iron dose (mg/mo)b 4.05 (−4.68 to 12.77)5.61 (−2.90 to 14.12)1.72 (−6.44 to 9.88)4.43 (−5.55 to 14.40)−3.43 (−7.79 to 0.93)−3.66 (−9.68 to 2.36)0.84
Ferritin (ng/ml)8.96 (0.53 to 17.38)7.07 (−5.89 to 20.03)2.02 (−3.55 to 7.58)2.05 (−6.30 to 10.40)19.79 (13.82 to 25.75)23.83 (16.31 to 31.35)0.74
Patients with ferritin≥800 ng/ml (%)0.99 (0.10 to 1.89)0.57 (−0.86 to 2.01)0.29 (−0.38 to 0.95)−0.15 (−1.19 to 0.89)1.93 (1.23 to 2.63)2.50 (1.78 to 3.22)0.43
Patients with ferritin≥1200 ng/ml (%)0.21 (−0.37 to 0.79)0.15 (−0.70 to 1.00)0.19 (−0.09 to 0.48)0.60 (−0.05 to 1.25)1.08 (0.72 to 1.44)0.88 (0.25 to 1.51)0.67
TSAT (%)−0.07 (−0.31 to 0.17)−0.05 (−0.37 to 0.27)0.24 (0.05 to 0.42)0.16 (−0.10 to 0.43)0.10 (−0.07 to 0.28)0.12 (−0.09 to 0.33)0.97
Patients with TSAT≥50% (%)0.14 (−0.21 to 0.49)0.04 (−0.55 to 0.63)0.09 (−0.23 to 0.42)0.18 (−0.26 to 0.62)0.01 (−0.28 to 0.29)0.17 (−0.21 to 0.56)0.50
  • Models adjusted for age, sex, predialysis weight, years since dialysis initiation, geographic region, and ESRD cause. 95% CI, 95% confidence interval; TSAT, transferrin saturation.

  • a Based on LDOs and a subset of non-LDOs.

  • b Based on a subset of facilities for which data were available.